Bifogade filer
XVIVO Interim Report January September 2024
Kurs
-2,66%
Likviditet
56,1 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2026-07-14 | 07:30 | Kvartalsrapport 2026-Q2 |
| 2026-04-22 | 07:30 | Kvartalsrapport 2026-Q1 |
| 2026-01-27 | 07:30 | Bokslutskommuniké 2025 |
| 2025-10-23 | 07:30 | Kvartalsrapport 2025-Q3 |
| 2025-07-11 | - | Kvartalsrapport 2025-Q2 |
| 2025-04-28 | - | X-dag ordinarie utdelning XVIVO 0.00 SEK |
| 2025-04-25 | - | Årsstämma |
| 2025-04-24 | - | Kvartalsrapport 2025-Q1 |
| 2025-01-28 | - | Bokslutskommuniké 2024 |
| 2024-10-24 | - | Kvartalsrapport 2024-Q3 |
| 2024-07-12 | - | Kvartalsrapport 2024-Q2 |
| 2024-04-26 | - | X-dag ordinarie utdelning XVIVO 0.00 SEK |
| 2024-04-25 | - | Årsstämma |
| 2024-04-24 | - | Kvartalsrapport 2024-Q1 |
| 2024-01-25 | - | Bokslutskommuniké 2023 |
| 2023-10-24 | - | Kvartalsrapport 2023-Q3 |
| 2023-07-13 | - | Kvartalsrapport 2023-Q2 |
| 2023-04-26 | - | X-dag ordinarie utdelning XVIVO 0.00 SEK |
| 2023-04-25 | - | Årsstämma |
| 2023-04-24 | - | Kvartalsrapport 2023-Q1 |
| 2023-01-26 | - | Bokslutskommuniké 2022 |
| 2022-10-27 | - | Kvartalsrapport 2022-Q3 |
| 2022-07-13 | - | Kvartalsrapport 2022-Q2 |
| 2022-04-27 | - | X-dag ordinarie utdelning XVIVO 0.00 SEK |
| 2022-04-26 | - | Årsstämma |
| 2022-04-25 | - | Kvartalsrapport 2022-Q1 |
| 2022-01-27 | - | Bokslutskommuniké 2021 |
| 2021-10-28 | - | Kvartalsrapport 2021-Q3 |
| 2021-07-13 | - | Kvartalsrapport 2021-Q2 |
| 2021-04-23 | - | X-dag ordinarie utdelning XVIVO 0.00 SEK |
| 2021-04-22 | - | Årsstämma |
| 2021-04-21 | - | Kvartalsrapport 2021-Q1 |
| 2021-01-28 | - | Bokslutskommuniké 2020 |
| 2020-10-23 | - | Kvartalsrapport 2020-Q3 |
| 2020-10-14 | - | Extra Bolagsstämma 2020 |
| 2020-07-10 | - | Kvartalsrapport 2020-Q2 |
| 2020-04-09 | - | Kvartalsrapport 2020-Q1 |
| 2020-04-01 | - | X-dag ordinarie utdelning XVIVO 0.00 SEK |
| 2020-03-31 | - | Årsstämma |
| 2020-01-30 | - | Bokslutskommuniké 2019 |
| 2019-10-24 | - | Kvartalsrapport 2019-Q3 |
| 2019-07-12 | - | Kvartalsrapport 2019-Q2 |
| 2019-04-26 | - | X-dag ordinarie utdelning XVIVO 0.00 SEK |
| 2019-04-25 | - | Årsstämma |
| 2019-04-24 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-08 | - | Bokslutskommuniké 2018 |
| 2018-10-26 | - | Kvartalsrapport 2018-Q3 |
| 2018-07-13 | - | Kvartalsrapport 2018-Q2 |
| 2018-04-30 | - | X-dag ordinarie utdelning XVIVO 0.00 SEK |
| 2018-04-27 | - | Årsstämma |
| 2018-04-26 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-09 | - | Bokslutskommuniké 2017 |
| 2017-10-27 | - | Kvartalsrapport 2017-Q3 |
| 2017-07-14 | - | Kvartalsrapport 2017-Q2 |
| 2017-04-27 | - | X-dag ordinarie utdelning XVIVO 0.00 SEK |
| 2017-04-26 | - | Årsstämma |
| 2017-04-25 | - | Kvartalsrapport 2017-Q1 |
| 2017-04-10 | - | Extra Bolagsstämma 2017 |
| 2017-02-08 | - | Bokslutskommuniké 2016 |
| 2016-10-27 | - | Kvartalsrapport 2016-Q3 |
| 2016-07-15 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-04 | - | X-dag ordinarie utdelning XVIVO 0.00 SEK |
| 2016-05-03 | - | Årsstämma |
| 2016-04-26 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-04 | - | Bokslutskommuniké 2015 |
| 2015-10-23 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-13 | - | Kvartalsrapport 2015-Q2 |
| 2015-04-24 | - | X-dag ordinarie utdelning XVIVO 0.00 SEK |
| 2015-04-23 | - | Årsstämma |
| 2015-04-22 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-05 | - | Bokslutskommuniké 2014 |
| 2014-10-24 | - | Analytiker möte 2014 |
| 2014-10-24 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-13 | - | Kvartalsrapport 2014-Q2 |
| 2014-04-30 | - | X-dag ordinarie utdelning XVIVO 0.00 SEK |
| 2014-04-29 | - | Årsstämma |
| 2014-04-23 | - | Kvartalsrapport 2014-Q1 |
| 2014-02-07 | - | Bokslutskommuniké 2013 |
| 2013-11-07 | - | Analytiker möte 2013 |
| 2013-11-07 | - | Kvartalsrapport 2013-Q3 |
| 2013-07-11 | - | Kvartalsrapport 2013-Q2 |
| 2013-05-08 | - | X-dag ordinarie utdelning XVIVO 0.00 SEK |
| 2013-05-07 | - | Årsstämma |
| 2013-04-19 | - | Kvartalsrapport 2013-Q1 |
| 2013-02-19 | - | Bokslutskommuniké 2012 |
| 2012-11-01 | - | Kvartalsrapport 2012-Q3 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Mid Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Third quarter 2024 (July 1 - September 30)
• Net sales amounted to SEK 198.5 million (146.6), corresponding to growth of 35 percent in SEK and 41 percent in local currencies.
• Organic growth accounted for 41 percent, and currency effects for -6 percent.
• The Business areas Thoracic and Abdominal delivered underlying organic growth adjusted for currency effects: Thoracic disposables 54 percent and Abdominal disposables 13 percent. The Services business area decreased by 7 percent.
• Gross margin for disposables was 81 percent (80). The total gross margin was 75 percent (73).
• Operating income (EBIT) amounted to SEK 20.5 million (5.3). Adjusted EBIT amounted to SEK 25.5 million (14.4).
• Operating income before depreciation and amortization (EBITDA) amounted to SEK 37.1 million (18.9) corresponding to an EBITDA margin of 19 percent (13). Adjusted operating income before depreciation and amortization (EBITDA) amounted to SEK 42.1 million (28.0), corresponding to an adjusted EBITDA margin of 21 percent (19).
• Net profit amounted to SEK 85.8 million (2.3) and was impacted by financial income of SEK 65.2 million (0.1) attributable to fair value valuation of financial liabilities. Earnings per share amounted to SEK 2.72 (0.08).
• Cash flow from operating activities was SEK 22.9 million (24.8). Total cash flow amounted to SEK -21.2 million (424.4) primarily impacted by investments in R&D projects, production facilities, and investments in machine installations at clinics.
Significant events in the quarter
• XVIVO’s European heart preservation study published in The Lancet
• XVIVO enters into an agreement to acquire FlowHawk - a unique communication platform for the transplant process. The transaction officially closed on October 11th
• Financial income of SEK 64.4 million recognized, attributable to write-down of financial liabilities after fair value valuation, not affecting cash flow, operating income (EBIT) or EBITDA
The period 2024 (January 1 - September 30)
• Net sales amounted to SEK 594.9 million (441.8), corresponding to growth of 35 percent in SEK and 36 percent in local currencies.
• Organic growth accounted for 36 percent, currency effect -1 percent.
• All business areas delivered underlying organic growth adjusted for currency effects: Thoracic disposables 44 percent, Abdominal disposables 31 percent and Services 4 percent.
• Gross margin for disposables was 80 percent (80). The total gross margin was 74 percent (74).
• Operating income (EBIT) amounted to SEK 72.9 million (20.3). Adjusted operating income (EBIT) amounted to SEK 79.1 million (41.9).
• Operating income before depreciation and amortization (EBITDA) amounted to SEK 124.2 million (59.8) corresponding to an EBITDA margin of 21 percent (14). Adjusted operating income before depreciation and amortization (EBITDA) amounted to SEK 130.1 million (81.4), corresponding to an adjusted EBITDA margin of 22 percent (18).
• Net profit increased to SEK 135.8 million (23.3) and was impacted by financial income of SEK 59.4 million (-1.7) attributable to fair value valuation of financial liabilities. Earnings per share amounted to SEK 4.31 (0.78).
• Cash flow from operating activities increased to SEK 49.2 million (28.2). Total cash flow amounted to SEK -91.7 million (341.4), primarily impacted by investments in R&D projects, production facilities, and investments in machine installations at clinics.
Significant events in the reporting period
• First-ever transplantation of a donor heart transported across the Atlantic - made possible by XVIVO’s heart technology
• Study in extended hypothermic (cold) perfusion of liver using Liver Assist shows that preservation can last up to 20 hours.
• Results from XVIVO’s European clinical trial, NIHP2019, in heart transplantation presented at ISHLT in Prague.
• New clinical study, ‘HOPE at Heart’, started by XVIVO in Europe on DCD hearts in 20 patients
• Unique initiative, ‘The Bridge – Lungs for Life’, started with the aim of increasing lung transplants in Sweden and Denmark
CEO comment
“The EVLP business in the US was the driving force this quarter, with our US clinical trial for heart also progressing as planned and staying within budget. With strong momentum in our US lung business, we enter the final part of the year with confidence. We are committed to invest in the need for more transplants as we steadily move closer to realizing our vision that nobody should die waiting for a new organ.” - Christoffer Rosenblad, CEO
For further information, please contact:
Christoffer Rosenblad, CEO, +46 73 519 21 59, e-mail: christoffer.rosenblad@xvivogroup.com
Kristoffer Nordström, CFO, +46 73 519 21 64, e-mail: kristoffer.nordstrom@xvivogroup.com
Conference Call
Christoffer Rosenblad, CEO and Kristoffer Nordström, CFO, will present the report in a conference call today at 2.00 PM CET / 8.00 AM EST. For registration to the conference call, see information in previous press release: https://www.xvivogroup.com/pressreleases/conference-call-on-interim-report-30/
About Us
Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs - so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq Stockholm under the ticker symbol XVIVO. More information can be found on the website www.xvivogroup.com.
This information is information that XVIVO Perfusion AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-10-24 07:30 CEST.